drugset / Trial / NCT06197139

A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors

NCT06197139 ↗

Phase 1 Recruiting 20 enrolled Xinlu Wang Sinotau Pharmaceutical Group · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a single-center, single-arm clinical study to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-XT117 injection in patients with FAP-positive advanced solid tumors.

Timeline

Start
2024-01
Primary completion
2025-12
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject [177Lu]Lu-XT117 Other / unclassified 3700 mbq —

Indications